Trial Profile
A phase II trial of trabectedin in soft tissue sarcoma patients with histological types reported to have chromosomal translocations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2015
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 07 Oct 2015 New trial record
- 28 Sep 2015 According to a Taiho Pharmaceutical media release, trabectedin 0.25 mg and 1 mg IV Infusion received marketing approval from the Ministry of Health, Labour and Welfare for the treatment of patients with soft tissue sarcoma in Japan. The results of this and two other trials supported this marketing approval.